{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Manocha N"],"funding":["Senior Research Fellowship from the Indian Council of Medical Research (ICMR), New Delhi","European Molecular Biology Organization (EMBO) Scientific Exchange"],"pagination":["316"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10975250"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(3)"],"pubmed_abstract":["Dengue virus (DENV) infection continues to be a public health challenge, lacking a specific cure. Vaccination remains the primary strategy against dengue; however, existing live-attenuated vaccines display variable efficacy across four serotypes, influenced by host serostatus and age, and predominantly inducing humoral responses. To address this limitation, this study investigates a multiepitope-based immunogen designed to induce robust cellular immunity across all DENV serotypes. The chimeric immunogen integrates H-2<sup>d</sup> specific MHC-I binding T-cell epitopes derived from conserved domains within the DENV envelope protein. Immuno-informatics analyses supported its stability, non-allergenic nature, and strong MHC-I binding affinity as an antigen. To assess the immunogenicity of the"],"journal":["Vaccines"],"pubmed_title":["Unveiling a Shield of Hope: A Novel Multiepitope-Based Immunogen for Cross-Serotype Cellular Defense against Dengue Virus."],"pmcid":["PMC10975250"],"funding_grant_id":["9401","VIR/Fellowship/35/2019-ECD-I"],"pubmed_authors":["Marvel J","Manocha N","Gueguen-Chaignon V","Gouet P","Robert X","Laubreton D","Kumar P","Khanna M"],"additional_accession":[]},"is_claimable":false,"name":"Unveiling a Shield of Hope: A Novel Multiepitope-Based Immunogen for Cross-Serotype Cellular Defense against Dengue Virus.","description":"Dengue virus (DENV) infection continues to be a public health challenge, lacking a specific cure. Vaccination remains the primary strategy against dengue; however, existing live-attenuated vaccines display variable efficacy across four serotypes, influenced by host serostatus and age, and predominantly inducing humoral responses. To address this limitation, this study investigates a multiepitope-based immunogen designed to induce robust cellular immunity across all DENV serotypes. The chimeric immunogen integrates H-2<sup>d</sup> specific MHC-I binding T-cell epitopes derived from conserved domains within the DENV envelope protein. Immuno-informatics analyses supported its stability, non-allergenic nature, and strong MHC-I binding affinity as an antigen. To assess the immunogenicity of the","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Mar","modification":"2026-07-09T11:06:51.175Z","creation":"2026-07-09T10:38:09.494Z"},"accession":"S-EPMC10975250","cross_references":{"pubmed":["38543950"],"doi":["10.3390/vaccines12030316"]}}